ADMA Biologics vs Ligand Pharmaceuticals
ADMA Biologics reported revenue of $510 million in fiscal 2025, 1.9 times Ligand Pharmaceuticals' $268 million in fiscal 2025. ADMA Biologics' revenue grew 19.6% in its latest year, and Ligand Pharmaceuticals' grew 60.4%. ADMA Biologics had an operating margin of 37.5%, against 15.3% at Ligand Pharmaceuticals. Free cash flow was $28 million at ADMA Biologics and $49 million at Ligand Pharmaceuticals.
Side by side
| ADMA Biologics | Ligand Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $510M | $268M |
| Revenue growth | 19.6% | 60.4% |
| Revenue growth a year, last 5 years | 64.6% | 10.4% |
| Gross margin | 57.4% | — |
| Operating margin | 37.5% | 15.3% |
| Net margin | 28.8% | 46.4% |
| Free cash flow | $28M | $49M |
| Free cash flow margin | 5.5% | 18.2% |
| Return on capital | 39.5% | 4.9% |
| Net debt to EBITDA | −0.1x | −3.8x |
| Dividends and buybacks | $32M | $15M |
| Change in diluted share count | 0.6% | 11.0% |
| Last close | $11.06 | $308.30 |
| P/E at the last close | 15.8× | 32.8× |
| Insider trades, last 12 months | bought $468,294, sold $1.6 million | sold $33.2 million |
| Piotroski F-score | 5 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ADMA BiologicsLigand Pharmaceuticals
Operating margin
Percent of revenue
ADMA BiologicsLigand Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ADMA BiologicsLigand Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ADMA Biologics and Ligand Pharmaceuticals pages.